Diabetes drug semaglutide under scrutiny for bone risks
NCT ID NCT07165158
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 32 times
Summary
This study looks at whether semaglutide, a common diabetes drug, affects bone density and fracture risk in people with type 2 diabetes. About 150 adults aged 50-75 with low bone mass or a recent fracture will take either semaglutide plus metformin or metformin alone for 12 months. Researchers will compare bone density, fracture rates, and bone markers between the two groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Conditions
Explore the condition pages connected to this study.